Overview
Watershed Informatics provides Watershed.bio, a subscription-based platform for analyzing multi-omics data used by researchers in academia, pharmaceutical companies, and biotech firms. The platform offers a web-based interface with data analysis workflows, visualization tools, and scalable infrastructure that helps users generate basic insights and publication-quality figures with minimal coding. It differentiates itself by acting as an active partner, offering infrastructure, data science expertise, and tailored services in addition to software. Its goal is to let clients focus on discovery by handling data processing, analysis pipelines, and expert support behind the scenes.
Work here?Claim your company
Simplify's Take
What believers are saying
- The 2023 $14.5M Series A from Canvas, Bessemer, and Accomplice funded commercialization.
- Watershed claimed ARR rose from $0 to $1M and team size doubled in 2023.
- Named users include Harvard Medical School, Stanford, UC San Diego, Revitope, and SQZ Biotech.
What critics are saying
- No current funding since 2023 suggests a long capital runway test by 2026.
- Recent evidence is mostly marketing pages, not hard revenue disclosures or major enterprise expansions.
- Crowded bioinformatics incumbents and internal platform teams can displace Omics Bench within 12 months.
What makes Watershed Informatics unique
- Omics Bench unifies bulk, single-cell, spatial, ATAC-Seq, and proteomics workflows in one cloud lab.
- Watershed sells to biologists and bioinformaticians, reducing coding dependence across R&D teams.
- Customers cite end-to-end bio-IT delivery at lower cost than traditional bioinformatics consulting.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards